Business
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues t
About this update from Catheter Precision, Inc.
[{"type":"image","alt":"Catheter Precision, Inc.","displaySize":"","headline":null,"caption":"Catheter Precision, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":274,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YQBzazT126278wVP0b5CKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c0002fcea5abba0697310d2b7733beb5","width":274,"height":58}},"lazy":false},{"type":"text","content":"FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include:","length":323,"tagName":"p"},{"type":"text","content":"Commercial Endeavors","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. The acquired assets include Cardionomic’s Cardiac Pulmonary Nerve Stimulation System, a new therapy under development based upon novel technology for the treatment of acute decompensated heart failure, or ADHF, for which over 1 million Americans are hospitalized annually. The acquired assets also include 49 issued patents and 46 patent applications.","length":529,"tagName":"p"}]},{"val":[{"type":"text","content":"Notice of the allowance from the US Patent Office of our first U.S. patent for our LockeT device.","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"The acquisition of PeriKard, LLC, a development stage company developing a kit of tools to enable physicians to more easily gain access to the pericardial space of the heart. It is intended that the kit will have both a better needle system and a better drainage system than current alternatives.","length":296,"tagName":"p"}]},{"val":[{"type...